Last edition
News about "Can-Fite BioPharma"
Can-Fite BioPharma announced the Chinese National Intellectual Property Administration has issued a Notice of Allowance for its patent titled An A3 Adenosine Receptor Ligand for use in Treating Ectopic Fat Accumulation. This patent addresses the use of the A3 Adenosine Receptor (A3AR) ligand, the target receptor for Can-Fite's drug platform technology
Can-Fite BioPharma | 20/06/2021 | By Darshana | 123
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members